Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grail, Inc. stock logo
GRAL
Grail
$26.14
+4.1%
$34.39
$12.33
$63.99
$886.02MN/A1.21 million shs1.18 million shs
Illumina, Inc. stock logo
ILMN
Illumina
$81.88
+4.5%
$99.22
$77.54
$156.66
$12.97B1.172.20 million shs1.91 million shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.27
+12.4%
$1.44
$1.08
$3.70
$378.27M1.8610.11 million shs10.21 million shs
Qiagen stock logo
QGEN
Qiagen
$40.06
+1.4%
$40.48
$37.63
$49.30
$8.89B0.441.08 million shs1.52 million shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$8.85
+2.1%
$11.70
$8.42
$37.74
$1.08B1.932.08 million shs3.16 million shs
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grail, Inc. stock logo
GRAL
Grail
+4.14%-7.93%-28.05%+45.87%+2,613,999,900.00%
Illumina, Inc. stock logo
ILMN
Illumina
+4.45%-1.15%-2.76%-37.46%-36.29%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
+12.39%0.00%-3.42%-29.44%-62.76%
Qiagen stock logo
QGEN
Qiagen
+1.40%+1.21%+4.84%-7.45%-2.41%
10x Genomics, Inc. stock logo
TXG
10x Genomics
+2.08%-7.62%-10.15%-37.63%-75.49%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Grail, Inc. stock logo
GRAL
Grail
0.7968 of 5 stars
1.03.00.00.03.20.80.6
Illumina, Inc. stock logo
ILMN
Illumina
4.794 of 5 stars
4.25.00.04.22.91.71.3
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.7089 of 5 stars
3.33.00.00.03.10.81.3
Qiagen stock logo
QGEN
Qiagen
3.5891 of 5 stars
2.23.00.04.51.91.71.3
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.7508 of 5 stars
4.23.00.04.82.64.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Grail, Inc. stock logo
GRAL
Grail
2.00
Hold$20.00-23.49% Downside
Illumina, Inc. stock logo
ILMN
Illumina
2.48
Hold$140.9072.08% Upside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.54
Moderate Buy$2.4693.57% Upside
Qiagen stock logo
QGEN
Qiagen
2.30
Hold$47.7119.09% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.35
Hold$20.21128.41% Upside

Current Analyst Ratings Breakdown

Latest ILMN, GRAL, TXG, PACB, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $2.00
3/22/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
3/18/2025
Grail, Inc. stock logo
GRAL
Grail
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $20.00
3/12/2025
Illumina, Inc. stock logo
ILMN
Illumina
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$247.00 ➝ $128.00
3/11/2025
Illumina, Inc. stock logo
ILMN
Illumina
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderweight ➝ Underweight
3/11/2025
Illumina, Inc. stock logo
ILMN
Illumina
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$156.00 ➝ $156.00
3/11/2025
Illumina, Inc. stock logo
ILMN
Illumina
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$135.00 ➝ $115.00
3/7/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
3/5/2025
Illumina, Inc. stock logo
ILMN
Illumina
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$127.00 ➝ $90.00
3/4/2025
Illumina, Inc. stock logo
ILMN
Illumina
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$130.00 ➝ $90.00
3/4/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Grail, Inc. stock logo
GRAL
Grail
$125.60M7.05N/AN/AN/A
Illumina, Inc. stock logo
ILMN
Illumina
$4.37B2.97$3.95 per share20.72$14.98 per share5.47
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$154.01M2.46N/AN/A$2.62 per share0.48
Qiagen stock logo
QGEN
Qiagen
$1.98B4.49$3.34 per share12.01$16.08 per share2.49
10x Genomics, Inc. stock logo
TXG
10x Genomics
$610.79M1.77N/AN/A$5.81 per share1.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Grail, Inc. stock logo
GRAL
Grail
N/AN/A0.00N/AN/AN/AN/AN/A5/15/2025 (Estimated)
Illumina, Inc. stock logo
ILMN
Illumina
-$1.22B-$7.68N/A15.871.60-27.95%13.37%5.49%5/1/2025 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$308.65M-$1.64N/AN/AN/A-200.40%-42.89%-14.77%5/8/2025 (Estimated)
Qiagen stock logo
QGEN
Qiagen
$83.59M$0.36111.5516.282.394.23%13.92%8.40%5/5/2025 (Estimated)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$182.63M-$1.52N/AN/AN/A-29.90%-25.40%-19.69%4/29/2025 (Estimated)

Latest ILMN, GRAL, TXG, PACB, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Illumina, Inc. stock logo
ILMN
Illumina
$0.94N/AN/AN/A$1.03 billionN/A
4/29/2025N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.46N/AN/AN/A$131.91 millionN/A
2/20/2025Q4 2024
Grail, Inc. stock logo
GRAL
Grail
-$4.41-$1.86+$2.55-$2.89$35.33 million$38.25 million
2/13/2025Q4 2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.20-$0.20N/A-$0.49$39.20 million$39.22 million
2/12/2025Q4 2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.32-$0.40-$0.08-$0.40N/AN/A
2/6/2025Q4 2024
Illumina, Inc. stock logo
ILMN
Illumina
$0.92$0.86-$0.06$1.17$1.08 billionN/A
2/5/2025Q4 2024
Qiagen stock logo
QGEN
Qiagen
$0.60$0.61+$0.01$0.39$518.54 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Grail, Inc. stock logo
GRAL
Grail
N/AN/AN/AN/AN/A
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
Qiagen stock logo
QGEN
Qiagen
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Grail, Inc. stock logo
GRAL
Grail
N/A
9.65
9.65
Illumina, Inc. stock logo
ILMN
Illumina
0.63
1.77
1.42
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.97
9.74
8.64
Qiagen stock logo
QGEN
Qiagen
0.38
3.61
3.09
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.97
4.26

Institutional Ownership

CompanyInstitutional Ownership
Grail, Inc. stock logo
GRAL
Grail
N/A
Illumina, Inc. stock logo
ILMN
Illumina
89.42%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
Qiagen stock logo
QGEN
Qiagen
70.00%
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Grail, Inc. stock logo
GRAL
Grail
N/A
Illumina, Inc. stock logo
ILMN
Illumina
0.17%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.40%
Qiagen stock logo
QGEN
Qiagen
9.00%
10x Genomics, Inc. stock logo
TXG
10x Genomics
10.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Grail, Inc. stock logo
GRAL
Grail
1,36033.90 millionN/AOptionable
Illumina, Inc. stock logo
ILMN
Illumina
9,030158.40 million158.13 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730297.85 million267.29 millionOptionable
Qiagen stock logo
QGEN
Qiagen
6,030221.86 million201.89 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,240122.30 million108.91 millionOptionable

Recent News About These Companies

2 Reasons to Sell TXG and 1 Stock to Buy Instead

New MarketBeat Followers Over Time

Media Sentiment Over Time

Grail stock logo

Grail NASDAQ:GRAL

$26.14 +1.04 (+4.14%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$24.90 -1.24 (-4.74%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

Illumina stock logo

Illumina NASDAQ:ILMN

$81.88 +3.49 (+4.45%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$79.11 -2.77 (-3.38%)
As of 04:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.27 +0.14 (+12.39%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$1.19 -0.08 (-6.30%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$40.06 +0.56 (+1.42%)
Closing price 04/2/2025 03:58 PM Eastern
Extended Trading
$40.95 +0.89 (+2.22%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$8.85 +0.18 (+2.08%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$8.42 -0.43 (-4.86%)
As of 04:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.